| DC3130 |
ICG-001
Featured
|
ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro |
|
| DC3115 |
ICI-118551
Featured
|
ICI-118,551 is a selective beta-2 (β2) adrenergic receptor antagonist.ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. |
|
| DC7213 |
ICILIN
Featured
|
Icilin is a synthetic super-agonist of the transient receptor potential M8 (TRPM8) ion channel. |
|
| DC8817 |
Icotinib Hydrochloride
Featured
|
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). |
|
| DC9639 |
iCRT 14
Featured
|
iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity).
|
|
| DC10680 |
iCRT3
Featured
|
iCRT3 is an inhibitor of both Wnt and β-catenin-responsive transcription. |
|
| DC20601 |
Idarubicin
Featured
|
Idarubicin Free Base is an orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. |
.png)
|
| DC8111 |
Idarubicin Hydrochloride
Featured
|
Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor. |
.gif)
|
| DC9970 |
IDE-1
Featured
|
IDE-1 induces definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 125 nM). |
|
| DC9971 |
IDE-2
Featured
|
IDE-2 is a cell-permeable inducer of definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 223 nM for induction of Sox17 expression in ESCs). |
|
| DC11782 |
IDF-11774
Featured
|
IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65 μM. |
|
| DC10538 |
IDH-305
Featured
|
IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. |
|
| DC10830 |
IDH-889
Featured
|
IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM. |
|
| DC10098 |
IDO-IN-1
Featured
|
IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM). |
|
| DC10421 |
IDO-IN-2
Featured
|
IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC50 values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell. |
|
| DC12541 |
iGOT1-01
Featured
|
iGOT1-01 is a small molecule inhibitor of aspartate aminotransferase 1 (glutamate oxaloacetate transaminase 1 (GOT1)) with IC50 of 11.3 uM. |
|
| DC8872 |
Iguratimod
Featured
|
Iguratimod is one of a series of 4H-1-benzopyran-4-ones which has potent anti-inflammatory, analgesic and antipyretic activity. |
|
| DC11258 |
IITZ-01
Featured
|
IITZ-01 is a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. |
|
| DC12547 |
GDC-0214(GDC0214)
Featured
|
GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2. |
|
| DC7158 |
IKK-16 HCl
Featured
|
IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively. |
|
| DC9485 |
IKK-16(free base)
Featured
|
IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.
|
|
| DC9484 |
IKK-2 inhibitor VIII
Featured
|
IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.
|
|
| DC7802 |
IKK(epsilon)-IN-1 (IKKE-IN-1)
Featured
|
IKKε-IN-1 is a potent IKKε inhibitor; inhibit the in-situ ΙKΚ ε-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM. |
|
| DC10205 |
Ilaprazole
Featured
|
Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM. |
|
| DC12631 |
IM176OUT05
Featured
|
IM176OUT05 is a novel, and safe small molecule that improves the acquisition and maintenance of stem cell pluripotency, inhibits electron transport chain (ETC) in the A549 lung carcinoma cell line with IC50 of 3.2 uM. |
|
| DC9242 |
Imatinib(free base)
Featured
|
Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. |
|
| DC4181 |
Imatinib mesylate
Featured
|
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
|
| DC8770 |
IMD-0354
Featured
|
IMD-0354 is a synthetic selective NF-kB inhibitor. |
|
| DC8890 |
Imidafenacin
Featured
|
Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM). |
|
| DC22092 |
Imidazole ketone erastin（IKE）
Featured
|
Imidazole ketone erastin (IKE, Ferroptosis inducer IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially suitable for in vivo applications. |
|
